Wichtige Ereignisse im Rückblick

Januar, März 2011 (E)
Blutspenden und XMRV

Oktober 2010 (E)
CFSAC Meeting 2010

23. Oktober 2011
Rituximab. Kann Krebsmittel ME/CFS-Patienten helfen?
(Deutsch und englisch)

Die Studie der Haukeland‐Universitätsklinik ist darum auch eine Bestätigung der Erfahrungen, die Scheibenbogen seit Jahren mit CFS‐Patienten macht. „Das ist ein Durchbruch bei der Behandlung dieser Krankheit“, resümiert Carmen Scheibenbogen. „Der Behandlungsansatz der Studie zielt darauf, das Immunsystem anzugreifen und führt zu einem Ergebnis: Den Patienten geht es besser. Etwas Vergleichbares gab es bislang nicht.“

Diesen Verdacht, dass das xenotrope murine Leukämie-Virus (XMRV) mit der Erkrankung in Zusammenhang steht, haben die norwegischen Wissenschaftler nicht ausgeräumt.
Die aktuellen Studienergebnisse deuten indessen auf immunologische Mechanismen beim Fatigue-Syndrom.

Der Wirkstoff Rituximab ist ein monoklonaler Antikörper, der zur Behandlung einer besonderen Form von Krebs der weißen Blutkörperchen, dem B-Zell Non-Hodgkin-Lymphom, eingesetzt wird. Daneben erhalten auch Patienten das Medikament, die unter einer besonders schweren Form der rheumatoiden Arthritis leiden. Die zu den Immunzellen gehören B-Lymphozyten prägen in einem bestimmten Entwicklungsstadium ein charakteristisches Eiweiß aus, das sogenannte CD20-Antigen. Die Funktion dieses Erkennungsmerkmals ist nicht vollständig klar. Es wird jedoch angenommen, dass es bei der Wachstumskontrolle eine Rolle spielt. Entartete B-Lymphozyten bilden dieses Eiweiß überdurchschnittlich häufig. An ihn bindet Rituximab gezielt und kann so die Tumorzellen unschädlich machen. Wie das Mittel die positive Wirkung bei den CSF-Patienten erzeugt haben könnte, darüber können die Wissenschaftler bislang nur spekulieren. Die deutliche Besserung spreche dafür "dass B-Lymphozyten eine wichtige Rolle beim Auslösen der Symptome spielen". Zudem weist die Studie auf mögliche Mechanismen hin, welche die Erkrankung auslösen.


Wikipedia
Was ist Rituximab?

Welt online
Lesen Sie mehr
Direkter Link




24. Oktober 2011
Spielen B-Lymphozyten eine wichtige Rolle beim Auslösen der Symptome von CFS?
(Deutsch und englisch)

Spiegel online
Lesen Sie mehr
Direkter Link

Direkt aus Norwegen
(Englisch)
Lesen Sie mehr
Direkter Link

Zurück zum Anfang

Oktober 2011 (D+E)
Judy Mikovits verlässt das Whittemore Peterson Institute. XMRV wahrscheinlich doch Laborkontamination?
(Deutsch und englisch)

Das gesamte WPI-Forschungsprogramm ist vom CEO (Firmenchef) des Instituts geschlossen worden, und die Einrichtung ist jetzt geschlossen. Ihre frühere leitende Forscherin, Dr. Judy Mikovits, steht in aktiven Verhandlungen mit Einrichtungen, zu denen sie wechseln kann, um ihre durch Forschungsgelder finanzierte Forschung fortzusetzen. Diese Institutionen müssen aus offensichtlichen Gründen ungenannt bleiben, aber es ist für die Patienten wichtig, zu wissen, dass sie weiterhin engagiert ist, um ihre entscheidende Arbeit fortzusetzen.

Jetzt gibt es also zu allem noch dazu eine Scheidung am WPI. Was noch kommen kann, sind all die Dinge, die in solch einer chaotischen Situation passieren könne. In der Zwischenzeit gibt es momentan keine von Mikovits geleitete Forschung am WPI oder an irgendeiner anderen Forschungseinrichtung. Ein enormer Verlust von Möglichkeiten


CFS-Aktuell
Direkter Link

Science (Englisch)
Lesen Sie mehr
Direkter Link


8. Oktober 2011
Die Ära Mikovits im WPI-Institut ist beendet 
(Englisch)

Phoenix Rising
Lesen Sie mehr
Direkter Link


4. Oktober 2011
Dr. Judy MIkovits wurde entlassen! XMRV wahrscheinlich doch Laborkontamination. 
(Englisch)

Wallstreet Journal
Lesen Sie mehr
Direkter Link

Chicago Tribune
Lesen Sie mehr
Direkter Link

Retraction Watch
Lesen Sie mehr
Direkter Link


Zurück zum Anfang

Gehirn von Patienten mit ME/CFS geschädigt

Zurück zum Anfang

Neue Konsenskriterien

Zurück zum Anfang

Neue Studien und Vorträge zu ME/CFS und/oder XMRV

Tagung bei den National Institutes of Health (NIH):

Stand von Wissenschaft und Forschung zu ME/CFS



Agenda

Schriftliche Berichterstattung

Berichterstattung des Events

Transkript oder als Word Datei


Zurück zum Anfang

Die wichtigsten Ereignisse von XMRV in einer Zeitleiste zusammengefasst

Die wichtigsten Ereignisse von XMRV in einer Zeitleiste zusammengefasst.
Klicken Sie bitte auf "Timeline." Danach auf der Webseite auf "View Timeline" und danach auf die gelben Punkte.


Zurück zum Anfang

Eine aktuelle Darstellung des Standes der Wissenschaft zu XMRV

Was ist XMRV (Xenotropic Murine Leukemia Virus-Related Virus)?
Verursacht es das Chronic Fatigue Syndrome?
Welche anderen Krankheiten könnten damit zusammenhängen?
Wie kann es behandelt werden?
XMRV ist die gegenwärtige Bezeichnung dieser kürzlich entdeckten Gruppe von Retroviren, die den Menschen infizieren. Es ist ein Mitglied der dritten bekannten Familie von humanen Retroviren, ein Humanes Gamma-Retrovirus (HGRV), und möglicherweise werden diese Viren zu gegebener Zeit in HGRV umbenannt werden. Das Humane Immundefizienz-Virus (HIV) und das Humane T-lymphotrope Virus (HTLV) sind die beiden anderen Familien humaner Retroviren, die einigen besser bekannt sein mögen.


Zurück zum Anfang

März 2011
XMRV and the Blood Supply: More Study Needed

Amy Dockser's latest health blog from the WSJ is really interesting. First of all it states that the Red Cross is starting to collect samples from no less than 10,000 donors to search for XMRV and XMLV's. Another study will look at,120 people have already received blood. The tests will be run by Gen-Probe and Abbott labs - neither of which is participating in the BWG study.

Abbott, of course, is a huge diagnostic lab that has been developing antibody and presumably other tests for XMRV. They have been closely involved in XMRV for quite some time. They co-sponsored, with the NIH, the International Workshop on XMRV in Sept of last year and Dr. Silverman is a paid consultant to the lab. They were involved in the primate study that evoked so much interest but an earlier Abbot antibody study found almost no XMRV in about 1,000 healthy donors. Gen Probe on the other hand said in Nov that it had developed a super sensitive test that could pick up XMRV before antibodies to it were formed.

Both studies are in the planning stages but sample collection will start soon. One wonders when testing will begin...It appears we're at least 6 months from any BWG conclusions about standardized assays...Will Abbott be using the same antibody test they used before? (And why do another test when Abbott's initial testing of about 1,000 samples was basically negative?) Will Gen Probe wait for the BWG findings??? Has the Red Cross - which also is not part of the BWG, decided that the Abbott and Gen Probe tests are accurate? It appears so.

Januar 2011
Amerikanisches Rotes Kreuz wird in 10'000 Blutproben nach XMRV suchen

Zurück zum Anfang

Dezember 2010
CFIDS Association Of America
XMRV Resource Page
(Wird laufend aktualisiert)


XMRV garnered a lot of headlines last month with eight new publications, a recommendation by an FDA advisory committee to add a question about CFS to blood donor questionnaires, and the report of interim data from an important blood safety study. Kim McCleary offers her perspective on the latest developments.
Zum Artikel

The CFIDS Asociation has updated the
XMRV Resources page to reflect studies published in late December and related media coverage:

  • Four studies and one editorial on possible routes of contamination in studies of murine leukemia virus-related viruses (Retrovirology)

  • A summary of the Sept. 2010 XMRV Workshop by the organizing committee (Retrovirology)

  • A paper proposing that XMRV might originate from contamination of vaccines or monoclonal antibodies (Frontiers in Virology)

For a summary of the data presented at conferences and in peer-reviewed publications for evidence of murine leukemia virus-related viruses (including XMRV) in CFS, check out our updated chart. We have also updated our comparison of published studies.

Drs. Graham Simmons, Michael Busch and Steven Kleinman presented a webinar on Dec. 17 to provide an update on the Blood XMRV Scientific Research Working Group's activities, including interim results of Phase II of the four-phase study. To learn more, view the
slides.

Researchers in Sweden and the U.S. reported a study of
45 twin pairs in which they found a weak association with hepatitis G virus in subjects with CFS or idiopathic chronic fatigue compared to their healthy twin. The group concluded that more study was needed to understand the significance of this finding. (BMC Microbiology).

Researchers at University of Miami and University of Alberta published data comparing levels of neuropeptide Y (NPY) in plasma samples taken from 93 CFS patients, 100 healthy sedentary controls and 37 individuals with Gulf War Illness.
NPY levels in CFS patients were higher than in either control group. Levels also correlated with some symptom severity measures, providing the potential for NPY to be used as a biomarker for CFS. The authors state that this data added to other information supports dysregulation of the hypothalamic-pituitary-adrenal axis in CFS, possibly due to infection. This study was funded in part by the CFIDS Association through a grant made in 2006. (Behavioral and Brain Functions).

The National Institutes of Health will convene a State of the Knowledge Workshop on ME/CFS Research on
April 7-8, 2011. This conference is being organized by a steering committee comprised of NIH staff, researchers and patient advocates. The meeting will be open to the public and they hope to be able to webcast it. More details will follow as the agenda, speakers and registration process are finalized.

The FDA's Blood Products Advisory Committee (BPAC) heard nine presentations about XMRV/MLVs at its
Dec. 14-15, 2010 meeting, including interim results of the Blood XMRV Scientific Research Working Group's study (see above). BPAC members voted 9-4 in favor of FDA asking donors about a medical history and/or diagnosis of CFS as a basis for indefinite deferral. All BPAC members indicated their support for indefinite deferral of individuals with a past/present diagnosis of CFS; there were differing opinions about whether asking a screening question was more or less effective than the current practice of giving all potential donors educational information about CFS. More information about blood donation and CFS is available on our website.

News & Notes

David Tuller of the New York Times recapped the latest research news in his Jan. 3, 2011 article,
"Exhausted by illness, and doubts." The article appeared on page D5 in the "Science News" section of the Jan. 4 print edition. A companion blog post, "The lingering mystery of CFS," by Toby Bilanow encouraged input from readers.

Author Laura Hillenbrand's new book Unbroken is at the top of the New York Times bestseller list and she recently sold the exclusive
screen rights to Universal Pictures. Laura has lived with severe CFS for 23 years and has spoken candidly about its impact on her life. Among the many recent articles about her are two from December in Sports Illustrated by Tim Layden: article and a follow-up interview.

The popular science podcast, "This Week in Virology," featured XMRV/MLVs (and CFS) on two recent episodes.
Episode 113 with guest Alan Rein of the National Cancer Institute covered the Retrovirology papers. (See "Research Matters" above.) Episode 114 was a recap of 10 stories from 2010; it led with XMRV and closed with "picks of the week" that included CEO Kim McCleary's article, "Headway, Headlines, and Healthy Skepticism."

The 7th International Conference on HHV-6 & 7 will be held in Reston, Vir., on Feb. 28-Mar. 2, 2011.
Abstracts are due Jan. 14, 2011.

The IACFS/ME will host the 10th International CFS/ME Research and Clinical Conference in Ottawa, Canada, Sept. 22-25, 2011. The conference theme is "Translating Evidence Into Practice" and
abstracts are due Mar. 15, 2011.

Dr. Linda Miller-Iger will receive the 2011
ATHENA Award for her contributions to CFS. Dr. Miller-Iger has conducted research and treated many CFS patients in her private practice, focusing attention on the neurocognitive difficulties experienced by adults and children with CFS. She was a frequent contributor to the CFIDS Chronicle in the 1990s.

Zurück zum Anfang

8. - 14. Oktober 2010
CFSAC Meeting 2010

On Oct. 12, 2010, the federal CFS Advisory Committee (CFSAC) will host a "science day" featuring presentations from six researchers studying various aspects of CFS pathophysiology. The session will be webcast live. According to the Federal Register notice, the purpose of this science day is to describe the latest developments in etiology, natural history, clinical trials and related areas. (See Public Policy Matters below for more info about the CFSAC meeting.)

Three of the six research teams funded by the CFIDS Association shared preliminary data from their projects, as well as other outcomes of Association support, during our Oct. 5 webinar, "Expanding Research: Building on Your Investment." Learn more about these teams' findings and how your support has spurred progress on validating biomarkers, understanding disease mechanisms and securing larger sums for CFS research. Participants were excited to hear about data sharing that's "connecting the dots" and about new funding awards and clues to target treatment.

It's been almost exactly a year since publication of the landmark study by Lombardi, et al. in Science that first associated CFS with the gammaretrovirus XMRV. Last month, 225 researchers met at the National Institutes of Health for the 1st International XMRV Workshop to share data and make sense of discrepant results in CFS and prostate cancer studies.
Here is more information about the meeting, including links to our detailed summary report, the webcast Q&A session and other meeting resources.

The latest publication reporting efforts to detect XMRV in CFS patients is from China, by Ping Hong, et al. Using polymerase chain reaction (PCR), the group tested peripheral blood mononuclear cells obtained from 65 CFS patients, 65 healthy blood donors and 20 control subjects infected with hepatitis B, hepatitis C, HIV-1 or HTLV. None of the samples were positive using methods reported in Virology Journal on Sept. 13, 2010.
We've updated our comparison of the published studies and regularly update our XMRV Resources page to reflect the latest studies.

Two letters to the editor of the Proceedings of the National Academy of Sciences were published on Sept. 30, 2010 with a response from Shyh-Ching Lo and other authors of the
FDA/NIH/Harvard study that reported polytropic murine leukemia virus sequences in 32 of 37 (86%) CFS patient samples tested. The conclusion of the response from Lo and colleagues states, "Our recent collaborative studies with a National Cancer Institute group have shown that we can detect antibodies in most patients with CFS with positive gag sequences and not in most PCR-negative subjects; studies on virus isolation are presently in progress. As we stated in the Discussion of our study, these and many other studies will be needed to better understand the true nature of association between murine retroviruses and CFS."

One of the topics raised frequently over the past year and discussed at the NIH workshop is the potential for laboratory artifacts of mouse DNA to confound studies of murine-related viruses. This subject received even more attention as a result of an opinion piece, "
A Cautionary Tale of Virus and Disease," published by Robin Weiss in BMC Biology on Sept. 27, 2010. Weiss is a retrovirologist who catalogued the many retroviruses that have been associated with human diseases, including several types of cancer, MS, lupus, psoriasis, schizophrenia and CFS, in a 2008 article titled, "Human RNA 'Rumor' Viruses: the Search for Novel Human Retroviruses in Chronic Disease."

Anthony Komaroff, MD, of Harvard Medical School, presented an Association webinar titled, "
CFS & the Viral Connection." on Sept. 16. Dr. Komaroff is a long-time CFS clinical researcher and is a collaborator on the FDA/NIH/Harvard study of murine leukemia viruses in CFS. He reviewed many important findings in CFS and related them to various infectious agents that have been associated with CFS over time, including XMRV and MLVs..


Das CFSAC-Meeting beginnt  | Link
U.S. Department of Health & Human Services (E) | Agenda
12.10.10 Video-Übertragung CFSAC-Meeting  | Video, Tag 1
13.10.10 Video-Übertragung CFSAC-Meeting | Video, Tag2
14.10.10 Video-Übertragung CFSAC-Meeting | Video, Tag3




Erster internationaler Workshop über XMRV




Zurück zum Anfang

August 2010
Replikationsstudie Alter/Lo

Am 23. August erschien in den Proceedings of the National Academy of Sciences (PNAS) die zunächst zurückgehaltene Studie von Harvey Alter und Shyh-Ching Loa, die die Ergebnisse der Original-Science-Studie von Lombardi/Mikovits zur Prävalenz des XMRV bestätigt.
Am Abend des 23. August 2010 veranstaltete das US-amerikanische National Institute of Health zusammen Vertretern der Food and Drug Administration (FDA) und der Centers for Disease Control (CDC) eine 40-minütige Online-Pressekonferenz über den möglichen Zusammenhang zwischen XMRV und ME/CFS.

Die Ergebnisse der FDA/NIH-Studie von Alter/Lo ergaben, dass 86,5% der Blutproben von ME/CFS-Patienten (32 von 37 Proben) positiv auf drei Varianten des XMRV waren, verglichen mit "nur" 6,8% der gesunden Kontrollgruppe (3 von 44 Proben).

Man hat nicht das XMRV gefunden, von dem in der Original-Science-Studie die Rede ist, sondern Variationen des XMRV, deren genetisches Material zu 96,6% identisch ist. Es handelt sich nicht um ein Virus, sondern um eine ganze Gruppe von Retroviren, sogenannte Murine leukemia viruses (MLVs). Harvey Alter sagte gegenüber CFScentral, dass Viren dazu tendieren, inhomogen zu sein. Sie würden sehr stark mutieren, und das beobachte man auch bei HIV und Hepatitis C.

National Academy of Sciences | Lesen Sie die Studie

NIH | Weitere Berichte und Kommentare

Transkript zur Online-Konferenz

Deutsche Zusammenfassung

Zurück zum Anfang